Trial Profile

A Multicentre, Phase II Randomized Study, Open-label, With 2-arm Parallel Group, Comparing the Pharmacokinetics of the Liquid and the Lyophilized Formulations of Pegaspargase (S95014) in Treatment of Paediatric Patients With Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 May 2026 Primary endpoint has been met. (Pharmacokinetics measurement), according to a results published in the Journal of Pediatric Hematology/Oncology.
01 May 2026 Primary endpoint has been met. (Pharmacokinetics measurement), according to results published in the Journal of Pediatric Hematology/Oncology.
01 May 2026 Results assessing the pharmacokinetics and safety of lyophilized and liquid pegaspargase in pediatric patients with ALL in Russia published in the Journal of Pediatric Hematology/Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com